GSK Acquires Nuvalent for $10.6 Billion, Marking Return to Oncology Sector
Here's what it means for you.
This acquisition signals a shift in GSK's strategy that could reshape the oncology landscape and impact market dynamics.
What happened
On June 9, 2026, GlaxoSmithKline (GSK) announced a $10.6 billion acquisition of Nuvalent, a U.S.-based cancer drug developer.
The Context
- Strategic Shift: GSK is returning to oncology after divesting its cancer business in 2014, aiming for substantial revenue growth by 2031.
- Pipeline Potential: Nuvalent's late-stage candidates for non-small-cell lung cancer could enhance GSK's portfolio and market position.
- Market Reaction: The acquisition has received mixed reactions, with GSK shares slipping initially as analysts weigh the risks and rewards.
The Number
— This significant investment underscores GSK's commitment to rebuilding its oncology portfolio and pursuing aggressive growth.
Takeaway
As GSK integrates Nuvalent, watch for shifts in the oncology market that could influence investment opportunities and healthcare strategies.
Public health, medical research, healthcare policy, and pharmaceutical developments.
"Dow Jones is a major financial news provider with a professional tone and broad coverage, including specialized health-sector reporting."
— A47 Editor
After shedding its cancer business just over a decade ago, GSK’s new CEO is building back with a $10.6 billion deal
GSK has announced a major acquisition of Nuvalent for $10.6 billion, marking a significant return to the oncology sector after divesting its cancer business over a decade ago. This strategic move is part of GSK's efforts to rebuild its portfolio in i...
Markets desk coverage, trading insights, and investor updates.
"WSJ’s markets reporting provides in-depth analysis and context for investors."
— A47 Editor
Health Care Roundup: Market Talk
GSK has announced its agreement to acquire Nuvalent, a U.S.-based cancer treatment firm, for $10.6 billion, marking a significant move to enhance its oncology portfolio under the leadership of new CEO Luke Miels. This acquisition is one of the larges...
UK and international business news, economics, and corporate coverage.
"The Guardian’s business section covers finance and markets with a progressive editorial tone."
— A47 Editor
GSK makes biggest ever acquisition with $10.6bn for US cancer drug firm
GSK has announced its largest acquisition to date, acquiring the US cancer drug firm Nuvalent for $10.6 billion. This deal includes the purchase of two late-stage lung cancer treatments, zidesamtinib and neladalkib, which are expected to launch later...
News from the United States including domestic politics, society, and culture.
"The Guardian is known for its progressive editorial stance and in-depth analysis, often advocating for social justice, environmental issues, and liberal values."
— A47 Editor
GSK makes biggest ever acquisition with $10.6bn for US cancer drug firm
GSK has announced its largest acquisition to date, acquiring the US cancer drug firm Nuvalent for $10.6 billion. This deal includes the purchase of two late-stage lung cancer treatments, zidesamtinib and neladalkib, which are expected to launch later...
Top international stories selected by The Guardian editors.
"The Guardian is known for its progressive editorial stance and in-depth analysis."
— A47 Editor
GSK makes biggest ever acquisition with $10.6bn for US cancer drug firm
GSK, the UK drugmaker, has announced its largest acquisition to date, acquiring Boston-based biotech firm Nuvalent for $10.6 billion. This deal, led by new CEO Luke Miels, aims to enhance GSK's oncology portfolio, particularly with Nuvalent's late-st...
Notable 10-K/10-Q/8-K, S-1/F-1, insider ownership changes, and other regulatory disclosures.
"Great for spotting material events and risk factors surfacing in filings."
— A47 Editor
GSK announces $10.6 billion agreement to acquire Nuvalent for oncology assets
GSK has announced a $10.6 billion agreement to acquire Nuvalent, a U.S.-based cancer treatment firm, marking one of the largest acquisitions under the leadership of new CEO Luke Miels. This strategic move aims to enhance GSK's oncology portfolio, par...
Editor-curated FT homepage stories spanning markets, business, world, and opinion.
"The Financial Times is a globally respected business publication with a centrist/center-left tone and strong markets focus."
— A47 Editor
GSK to buy US cancer biotech Nuvalent for $10.6bn
GSK has announced its agreement to acquire Nuvalent, a U.S.-based cancer biotech firm, for $10.6 billion, marking one of the largest deals under the leadership of new CEO Luke Miels. This acquisition aims to enhance GSK's oncology portfolio, particul...
Market-moving headlines impacting equities, bonds, and related risk assets.
"Real-time catalysts and volatility drivers across indices and sectors."
— A47 Editor
GSK shares fall following $10.6 bln Nuvalent acquisition deal
GSK's shares experienced a decline following the announcement of its $10.6 billion acquisition of Nuvalent, a U.S. cancer treatment firm. This acquisition is one of the largest under the leadership of new CEO Luke Miels and aims to bolster GSK's onco...
Global markets, investing, and macroeconomics from a premier financial newsroom.
"Bloomberg is respected for in-depth financial reporting and data-driven analysis."
— A47 Editor
GSK Agrees to Buy Nuvalent for $10.6 Billion
GSK has agreed to acquire Nuvalent, a U.S.-based cancer treatment firm, for $10.6 billion, a significant move aimed at strengthening its oncology portfolio. This acquisition is one of the largest under the leadership of new CEO Luke Miels and reflect...
U.S. business news, corporate developments, and economy.
"The Wall Street Journal is respected for deep financial and economic reporting with a center-right editorial perspective."
— A47 Editor
GSK to Buy Nuvalent for $10.6 Billion in Oncology Push
GSK has announced its acquisition of Nuvalent for $10.6 billion, a strategic move aimed at enhancing its oncology portfolio. This acquisition grants GSK ownership of three drug candidates for lung cancer, with two currently under FDA review for appro...
Market-moving headlines impacting equities, bonds, and related risk assets.
"Real-time catalysts and volatility drivers across indices and sectors."
— A47 Editor
GSK in talks to buy cancer drugmaker Nuvalent for over $9 bln, FT reports
GSK is reportedly in discussions to acquire cancer biotech company Nuvalent for over $9 billion, a move that could significantly enhance GSK's portfolio in oncology. This potential acquisition reflects GSK's strategic focus on expanding its capabilit...